Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NICE.... It may just make this tool even more deadly!!!!!
JimBob
Hey Lou, I would like laymen definitions for all of the settings. Something in-depth but written in a way that is easy for the mathmatically challenged to understand. Kind of like the dummy books.
Thanks Jim
P.S. I love this software.. It has changed my life..
I am catching up to the StockWerld Gold Port.... I wish.. ehhehehe
Jim
Up 6.67% on recent GGUY purchase.. Holy SMOKES!!!!
JimBob
http://www.vestorAnalytics.com
X_Dev Rocks... Up 2.7% on ACF from recent purchase!!!!
YEEEE HAAAAA
http://www.vestorAnalytics.com
Look at INTI. Like I said in earlier posts I find them, open a position, get back out and then the stock shoots up..
AAAAAAHHHHHHHHHHHHHHHHHHHHH!!!!!!!!!!!!!!!!!
Did it again....
JimBob
http://www.vestorAnalytics.com
New Jobs data is disapointing, the correction may continue.
Finding a low priced stock with improving fundamentals and decent liquidity is like finding a needle in a haystack.
JimBob
DFIB, another one of Kaye's picks has the X_Dev buy right at support. This one could possibly get a buy signal tomorrow. Nice looking chart. Still need to DD it. You might want to check it out.
JimBob
Kaye's pick RSTO should hit a buy signal tomorrow. I am going to do some DD on it to see if I might jump in.
Nice looking pick, way to go Kaye.
Kaye has a very interesting TC2000 scan she uses to find low cost stocks in an uptrend. I post her picks on my site for those that are interested. She also explanes her trading plan, which I find very informative.
JimBob
http://www.vestorAnalytics.com
kedew, Here it is:
75% Profit over 18% B&H
9-11-02
30000
15
66
2700
4
200
200
3
0
That 2700 is a way-out number but it seems to be working quite well.
JimBob
http://www.vestorAnalytics.com
Still holding small partial pos on BBY.
JimBob
X_Dev buy on GGUY today.. risky.. poor financials.. another X_Dev test. :)
JimBob
http://www.vestorAnalytics.com
X_Dev buy today on ACF.. Yee Haa
JimBob
http://www.vestorAnalytics.com
Thanks, I was there and could not find the link to download the data. I am adding charting capabilities to the site and the silicon valley investor seems to be a little better than yahoo. Do I need to email them?
Thanks again, Jim
Should be getting a buy signal for ACF tomorrow.
Jim
Hey Myst, what is the website address where you get the Silicon Valley Investor price data from?
Thanks Jim
SHRP: This Budd is for you, :O)
Just coming out of it's biggest month of the year from a historical standpoint:
http://insider.thomsonfn.com/tfn/stocks.asp?imodule=seasonality&ticker=shrp&ttype=A
Scorecard looks good:
http://www.quicken.com/investments/strategies/?p=shrp
Recent good news:
http://cbs.marketwatch.com/news/newsfinder/newsArticles.asp?guid=%7B2A68E013%2DED2C%2D437C%2DA3ED%2D....
No insider buying:
http://www.nasdaq.com/asp/holdings.asp?mode=&kind=&symbol=SHRP&symbol=&symbol=&s....
Recent institutional selling proposed on form 144:
http://www.nasdaq.com/asp/holdings.asp?mode=&kind=&symbol=SHRP&symbol=&symbol=&s....
Short interest increasing:
27% of the float is short
http://www.nasdaq.com/asp/quotes_full.asp?mode=&kind=shortint&symbol=SHRP&symbol=&sy....
Take a look at a weekly chart, looks like a double top???
On the daily chart I see a widening wedge with the next stop at about $16.25.
This one is not for me for the short term, but long term I will keep my eye on it.
Thanks,
JimBob
Anyone here?
FuzzDuzz, here are my settings for RGLD.
8-1-02
5000
15
66
3
13
50
50
7.5
4
42% vs. 34.88
Jim
Thanks FuzzDuzz, this is a combined effort between an economist friend of mine from Barcelona, Spain and myself. I don't want to take all the credit. He is great with his fundamental and news research. I guess he should be.. ehheheh
JimBob
http://www.vestorAnalytics.com
Here is recent pick I am playing, with X_Dev and fundamental research included. http://www.vestorAnalytics.com
AVAN Avant Immunotherapeutics Inc (NASDAQ NM)
Rating: Speculative Short/Long Term Buy
Date of Recommendation: 11/26/2002
Price: $1.20
SYNOPSIS:
AVAN is definitively a very interesting pick with a great potential upside for the short and long term.
Speculation on War with Iraq and bioterrorism are excellent arguments to build momentum.
The core business of the company is the research, production and commercialization of vaccines for the prevention of diseases and among them of particular note those related to protection of military personnel and civilians against bacterial and viral agents used in biowarfare or terrorist activities.
Under the current political environment the demand for such products is definitively poised to get a boost.
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fse...
"CONGRESS RECENTLY approved an 18% increase in military R&D, to $58.8 billion for the current fiscal year — more money, after accounting for inflation, than the Pentagon ever spent on research during the Cold War. Early next year, the National Institutes of Health is in line for a similar-size boost to around $26 billion, partly to examine biological-warfare defenses. In all, the federal government will likely spend about $115 billion on R&D in the year ending Sept. 30, far more than Japan and the 15 European Union governments will spend collectively."
FINANCIALS:
The company has no debt and a cash position of
$31.7M.
Particularly of note is the financial progression of the revenues with a sequential increase between the last 2 qtrs of 610%
Sept 30 2002 / Jun 30 2002 / Mar 31, 2002
$4,560,400 / $642,700 / $690,900
and Net Loss decreased 95%
Sept 30 2002 / Jun 30 2002 / Mar 31, 2002
($276,200) / ($5,164,300) / ($4,913,600)
http://biz.yahoo.com/fin/l/a/avan.html
TA (chart):
From a technical analysis perspective the chart pattern (daily time frame) shows a perfect bullish trend with the price currently close to the base of the channel.
Today the stock crossed over and closed above EMAs (13,20 & 50) on a volume almost double than average.
Currently the stock is oversold: RSI(14)= 25 and stochastics coming out of the 20s area after a positive cross.
FIRMS THAT WILL BENEFIT FROM THE NEW BATTLE AGAINST BIOTERRORISM:
MOVING TARGETS
Avant Immunotherapeutics (Nasdaq: AVAN) CEO Dr. Una Ryan said as much on October 23 at a hearing on biological warfare defense vaccine research-and-development programs in front of the House Committee on Government Reform Subcommittee on National Security, Veterans Affairs, and International Relations.
Dr. Ryan told the committee of some of the difficulties in combating a bioterrorist attack, such as distributing drug treatments to a large exposed population and the relative ease with which an attacker can create mutant drug-resistant strains. "In addition to the same logistical problems," she said, "the antidote approach must contend with the fact that the organism that causes anthrax, Bacillus anthracis, is in itself not the cause of illness or death, but rather the producer of toxins that ultimately kill its host or rapidly trigger downstream havoc in the body."
Avant is developing vaccines designed, as Dr. Ryan put it, to "prevent the establishment of virulence and subsequent toxin production if the bacteria were to be encountered through any of the known routes: inhalation, ingestion, or skin contact."
http://www.redherring.com/insider/2001/1026/240020424.html
Review of Additional Events During last Quarter
Bioterrorism Vaccines
In early July, AVANT was awarded a Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) to support the development of the company's single oral-dose bacterial vectors to immunize people against anthrax. The proposed bacterial vectors are derived from AVANT's cholera and typhoid fever vaccines currently in clinical development. During the quarter, AVANT has been active in ongoing discussions with the U.S. government regarding development of vaccines to protect against bioterrorism agents.
Last week AVANT announced that its partner, DynPort Vaccine Company LLC (DVC), will enter into a Phase I clinical trial of a new injectable recombinant anthrax vaccine in approximately 70 volunteers. The vaccine candidate consists of a highly purified protein - Protective Antigen - derived from the anthrax bacterium using recombinant technology and advance production processes licensed from AVANT. DVC hopes this vaccine will offer a safe, effective product to support the country's need for a new-generation anthrax vaccine.
Bacterial Vaccines
On September 30, 2002, AVANT announced successful results of a Phase II dose-ranging study of its investigational cholera vaccine, Peru-15. The objectives of this study were to evaluate the safety, immunogenicity and dose-response relationship of the vaccine with the aim of optimizing dosage and evaluating a new buffer system prior to undertaking larger-scale clinical studies.
"The excellent results from this trial have allowed us to establish that a single dose produces an effective immune response," said Alistair Wheeler, MD, Vice President, Medical Affairs of AVANT Immunotherapeutics. "The vaccine was well tolerated in vaccinated individuals, results confirm that the new buffer system works well with Peru-15, and the study generated sufficient data to describe a dose-response relationship for the vaccine. We are pleased that the results of this study provide a solid basis for the further clinical development of Peru-15."
Cholesterol Management Vaccine
During the quarter, AVANT also completed enrollment in the placebo-controlled Phase II study of its cholesterol management vaccine (CETi-1) in approximately 200 subjects with low levels of HDL (high-density lipoprotein) cholesterol. The company is half way through this important two-year study and on schedule to report results in the second half of 2003.
Animal Health and Food Safety Vaccines
Additionally, AVANT has appointed Lohmann Animal Health International (LAHI) as the exclusive distributor of its Megan Health poultry vaccines in North America, which AVANT believes leverages the value of its oral vaccine technology in a significant market opportunity outside of AVANT's own focus on human health care.
"AVANT has made significant progress in leveraging the value of its vaccine technologies for multiple human healthcare needs, as well as applications in animal health and food safety," commented Dr. Ryan.
UPCOMING EVENTS:
AVAN to present at the Bill Gates Foundation/Global Health Forum Dec 3-5, Washington DC:
http://biospace.com/news_story.cfm?StoryID=10875420
http://biospace.com/news_story.cfm?StoryID=10875420&full=1
Companies Researching Diseases Of Developing Nations To Present At Gates Foundation/Biotechnology Industry Organization (BIO) Global Health Forum
WASHINGTON, Nov. 21 /PRNewswire/ -- Today the Biotechnology Industry Organization (BIO) and the Bill & Melinda Gates Foundation announced the participation of 20 biotechnology companies who will present their technologies at the Partnering for Global Health Forum, Dec. 3-5, at the Omni Shoreham Hotel in Washington. The forum will bring together industry leaders, potential funders and international health experts to discuss how biotechnology can be used to find treatments and cures for diseases in the developing world. These diseases include HIV/AIDS, tuberculosis, and malaria.
Each of the presenting biotechnology companies are researching and developing technologies and products to address these neglected diseases. The companies will present developments important to improving global health to an audience comprised of government procurement officials, private foundations, public-private partnership organizations, and investors.
Below is a list of presenting companies. Please visit
http://www.bio.org for complete information.
* Advanced Life Sciences, Inc.
* AlphaVax, Inc.
* AVANT Immunotherapeutics, Inc.
* Cambria Biosciences LLC
* Cellestis Ltd.
* Corixa Corporation
* Divergence, Inc.
* HandyLab, Inc.
* Hollis-Eden Pharmaceuticals
* Iguazu Biosciences
* Institute for OneWorld Health
* Immtech International, Inc.
* Iomai Corporation
* Maxygen, Inc.
* Mojave Therapeutics, Inc.
* OmniViral Therapeutics, LLC
* Sequella, Inc.
* VaxGen, Inc.
* ViroLogic, Inc.
* Zentaris AG
Confirmed speakers for the forum include Dr. Elias Zerhouni, director of the National Institutes of Health (NIH); Dr. David L. Heymann, executive director of communicable diseases for the World Health Organization (WHO); Carl B. Feldbaum, president of BIO; Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID); Richard G.A. Feachem, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria; Laurie Garrett, winner of the Pulitzer, Polk and Peabody Prize and author of "The Coming Plague"; and Dr. Richard Klausner, executive director of Global Health for the Bill & Melinda Gates Foundation.
Complimentary press registration is available for credentialed members of the news media. Advance press registration has been extended until Dec. 2, please visit http://www.bio.org to register. Onsite media registration begins Wednesday, Dec. 4 at 7:00 a.m.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.
Here is recent pick I am playing, with X_Dev and fundamental research included. http://www.vestorAnalytics.com
AVAN Avant Immunotherapeutics Inc (NASDAQ NM)
Rating: Speculative Short/Long Term Buy
Date of Recommendation: 11/26/2002
Price: $1.20
SYNOPSIS:
AVAN is definitively a very interesting pick with a great potential upside for the short and long term.
Speculation on War with Iraq and bioterrorism are excellent arguments to build momentum.
The core business of the company is the research, production and commercialization of vaccines for the prevention of diseases and among them of particular note those related to protection of military personnel and civilians against bacterial and viral agents used in biowarfare or terrorist activities.
Under the current political environment the demand for such products is definitively poised to get a boost.
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fse...
"CONGRESS RECENTLY approved an 18% increase in military R&D, to $58.8 billion for the current fiscal year — more money, after accounting for inflation, than the Pentagon ever spent on research during the Cold War. Early next year, the National Institutes of Health is in line for a similar-size boost to around $26 billion, partly to examine biological-warfare defenses. In all, the federal government will likely spend about $115 billion on R&D in the year ending Sept. 30, far more than Japan and the 15 European Union governments will spend collectively."
FINANCIALS:
The company has no debt and a cash position of
$31.7M.
Particularly of note is the financial progression of the revenues with a sequential increase between the last 2 qtrs of 610%
Sept 30 2002 / Jun 30 2002 / Mar 31, 2002
$4,560,400 / $642,700 / $690,900
and Net Loss decreased 95%
Sept 30 2002 / Jun 30 2002 / Mar 31, 2002
($276,200) / ($5,164,300) / ($4,913,600)
http://biz.yahoo.com/fin/l/a/avan.html
TA (chart):
From a technical analysis perspective the chart pattern (daily time frame) shows a perfect bullish trend with the price currently close to the base of the channel.
Today the stock crossed over and closed above EMAs (13,20 & 50) on a volume almost double than average.
Currently the stock is oversold: RSI(14)= 25 and stochastics coming out of the 20s area after a positive cross.
FIRMS THAT WILL BENEFIT FROM THE NEW BATTLE AGAINST BIOTERRORISM:
MOVING TARGETS
Avant Immunotherapeutics (Nasdaq: AVAN) CEO Dr. Una Ryan said as much on October 23 at a hearing on biological warfare defense vaccine research-and-development programs in front of the House Committee on Government Reform Subcommittee on National Security, Veterans Affairs, and International Relations.
Dr. Ryan told the committee of some of the difficulties in combating a bioterrorist attack, such as distributing drug treatments to a large exposed population and the relative ease with which an attacker can create mutant drug-resistant strains. "In addition to the same logistical problems," she said, "the antidote approach must contend with the fact that the organism that causes anthrax, Bacillus anthracis, is in itself not the cause of illness or death, but rather the producer of toxins that ultimately kill its host or rapidly trigger downstream havoc in the body."
Avant is developing vaccines designed, as Dr. Ryan put it, to "prevent the establishment of virulence and subsequent toxin production if the bacteria were to be encountered through any of the known routes: inhalation, ingestion, or skin contact."
http://www.redherring.com/insider/2001/1026/240020424.html
Review of Additional Events During last Quarter
Bioterrorism Vaccines
In early July, AVANT was awarded a Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) to support the development of the company's single oral-dose bacterial vectors to immunize people against anthrax. The proposed bacterial vectors are derived from AVANT's cholera and typhoid fever vaccines currently in clinical development. During the quarter, AVANT has been active in ongoing discussions with the U.S. government regarding development of vaccines to protect against bioterrorism agents.
Last week AVANT announced that its partner, DynPort Vaccine Company LLC (DVC), will enter into a Phase I clinical trial of a new injectable recombinant anthrax vaccine in approximately 70 volunteers. The vaccine candidate consists of a highly purified protein - Protective Antigen - derived from the anthrax bacterium using recombinant technology and advance production processes licensed from AVANT. DVC hopes this vaccine will offer a safe, effective product to support the country's need for a new-generation anthrax vaccine.
Bacterial Vaccines
On September 30, 2002, AVANT announced successful results of a Phase II dose-ranging study of its investigational cholera vaccine, Peru-15. The objectives of this study were to evaluate the safety, immunogenicity and dose-response relationship of the vaccine with the aim of optimizing dosage and evaluating a new buffer system prior to undertaking larger-scale clinical studies.
"The excellent results from this trial have allowed us to establish that a single dose produces an effective immune response," said Alistair Wheeler, MD, Vice President, Medical Affairs of AVANT Immunotherapeutics. "The vaccine was well tolerated in vaccinated individuals, results confirm that the new buffer system works well with Peru-15, and the study generated sufficient data to describe a dose-response relationship for the vaccine. We are pleased that the results of this study provide a solid basis for the further clinical development of Peru-15."
Cholesterol Management Vaccine
During the quarter, AVANT also completed enrollment in the placebo-controlled Phase II study of its cholesterol management vaccine (CETi-1) in approximately 200 subjects with low levels of HDL (high-density lipoprotein) cholesterol. The company is half way through this important two-year study and on schedule to report results in the second half of 2003.
Animal Health and Food Safety Vaccines
Additionally, AVANT has appointed Lohmann Animal Health International (LAHI) as the exclusive distributor of its Megan Health poultry vaccines in North America, which AVANT believes leverages the value of its oral vaccine technology in a significant market opportunity outside of AVANT's own focus on human health care.
"AVANT has made significant progress in leveraging the value of its vaccine technologies for multiple human healthcare needs, as well as applications in animal health and food safety," commented Dr. Ryan.
UPCOMING EVENTS:
AVAN to present at the Bill Gates Foundation/Global Health Forum Dec 3-5, Washington DC:
http://biospace.com/news_story.cfm?StoryID=10875420
http://biospace.com/news_story.cfm?StoryID=10875420&full=1
Companies Researching Diseases Of Developing Nations To Present At Gates Foundation/Biotechnology Industry Organization (BIO) Global Health Forum
WASHINGTON, Nov. 21 /PRNewswire/ -- Today the Biotechnology Industry Organization (BIO) and the Bill & Melinda Gates Foundation announced the participation of 20 biotechnology companies who will present their technologies at the Partnering for Global Health Forum, Dec. 3-5, at the Omni Shoreham Hotel in Washington. The forum will bring together industry leaders, potential funders and international health experts to discuss how biotechnology can be used to find treatments and cures for diseases in the developing world. These diseases include HIV/AIDS, tuberculosis, and malaria.
Each of the presenting biotechnology companies are researching and developing technologies and products to address these neglected diseases. The companies will present developments important to improving global health to an audience comprised of government procurement officials, private foundations, public-private partnership organizations, and investors.
Below is a list of presenting companies. Please visit
http://www.bio.org for complete information.
* Advanced Life Sciences, Inc.
* AlphaVax, Inc.
* AVANT Immunotherapeutics, Inc.
* Cambria Biosciences LLC
* Cellestis Ltd.
* Corixa Corporation
* Divergence, Inc.
* HandyLab, Inc.
* Hollis-Eden Pharmaceuticals
* Iguazu Biosciences
* Institute for OneWorld Health
* Immtech International, Inc.
* Iomai Corporation
* Maxygen, Inc.
* Mojave Therapeutics, Inc.
* OmniViral Therapeutics, LLC
* Sequella, Inc.
* VaxGen, Inc.
* ViroLogic, Inc.
* Zentaris AG
Confirmed speakers for the forum include Dr. Elias Zerhouni, director of the National Institutes of Health (NIH); Dr. David L. Heymann, executive director of communicable diseases for the World Health Organization (WHO); Carl B. Feldbaum, president of BIO; Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID); Richard G.A. Feachem, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria; Laurie Garrett, winner of the Pulitzer, Polk and Peabody Prize and author of "The Coming Plague"; and Dr. Richard Klausner, executive director of Global Health for the Bill & Melinda Gates Foundation.
Complimentary press registration is available for credentialed members of the news media. Advance press registration has been extended until Dec. 2, please visit http://www.bio.org to register. Onsite media registration begins Wednesday, Dec. 4 at 7:00 a.m.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.
Hey Myst, hahhahahah... The IFport you are looking at is the old test port from the proving grounds test I ran when I first purchased X_Dev.
Go X_Dev.. hehehehhe
I have started a new port on my website.. It will take a while to build the profits up on that one.
Thanks for noticing.
JimBob
http://www.vestorAnalytics.com
Allaf----BBY
I had entered a partial pos in BBY after it had gone up for 3 days after the last X_Dev sell signal. Glad I did.. Nice pop today. Now I follow the rule and disregard all further sell signals and wait for the next X_Dev Buy signal and add to the pos.
Note. Insiders started selling again yesterday..
JimBob
http://www.vestorAnalytics.com
Happy Thanksgiving everyone.
I will post it on the site tonight.
Thanks Kaye,
JimBob
http://www.vestorAnalytics.com
Myst, How bout one of those Mystical setups for INTI.
Here is mine:
6-28-02
11-25-02
590
11
66
20
14
25
25
8
-1.8
Also.. If you find a stock you want to trade with X_Dev and a buy signal was just triggered a few days before but price is now lower, do you go ahead and enter the trade at the current price?
JimBob
http://www.vestorAnalytics.com
Hey Myst, I am looking and SEBL. Based on the Lit Wick Co. would the last 3 day qualify as "side-by-side white lines" in your opinion?
Jim
Kewl, thanks..
Hey Myst, are you having any luck with the MSN screen. I have been fooling around with it and I am not getting anywhere.
JimBob
BBY is for me.. I have already made the re-entry on the third day. I waited until the close to make sure that price would stay above the horizontal resistance line you show in your chart. Now I wait for X_Dev to do the rest...
JimBob
http://www.vestorAnalytics.com
What does "gg" stand for? Thanks..
Lock Tender, check your email....
JimBob
Frank, I got ya all fixed up...
JimBob
Hey Nimubus, what about using trailing stops then. Maybe tighten the stops up as price nears the sell band, but if it keeps going your still in and don't loose the optimum X_Dev setup.
Let me know what you think,
JimBob
Hey Myst, how much you charge for the proprietary Myst Scan you use to find those babies?
JimBob
I place my limit orders the night before based on the forecast.
JimBob
http://www.vestorAnalytics.com
Nimbus, I agree and therefore I tend to re-adjust X_Dev settings more often or use other T/A means to trade the stocks in combination with X_Dev. Similar to Myst's 50% re-entry plan when the trend continues, I use similar kinds of strategies based on chart patterns, etc. If the stock looks weak I may put a stop in above the next X_Dev buy signal and so on. I am not a black box guy and always want my foot on the brake and the gas. I just have to learn how to coast every now and then.. hahahhaha
Talk to ya soon, JimBob
http://www.vestorAnalytics.com
Up 24% in ACF.. GOOOO X_Dev!!!!!
JimBob
http://www.vestorAnalytics.com